azacitidine has been researched along with pyrimidinones in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Adams, FF; Alwie, Y; Gabdoulline, R; Ganser, A; Gupta, C; Heckl, D; Heuser, M; Humphries, RK; Imren, S; Jyotsana, N; Kattre, N; Kloos, A; Mintzas, K; Schambach, A; Scherr, M; Schottmann, R; Schwarzer, A; Thol, F; Winckler, L | 1 |
Feige, U; Hamed, E; Hanft, KM; Hettmer, S; Kaiser, M; Krengel, S; Meiss, F; Niemeyer, C; Pietsch, T; Schneider, M; Würtemberger, J | 1 |
Borthakur, G; Chien, KS; Daver, N; DeLumpa, R; Desikan, SP; Jabbour, EJ; Jain, N; Kadia, TM; Konopleva, M; Kwari, M; Loghavi, S; Macaron, W; Maiti, A; Montalban-Bravo, G; Pemmaraju, N; Ravandi, F; Short, NJ | 1 |
1 trial(s) available for azacitidine and pyrimidinones
Article | Year |
---|---|
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase Kinases; Mutation; Pyridones; Pyrimidinones; Sulfonamides | 2022 |
2 other study(ies) available for azacitidine and pyrimidinones
Article | Year |
---|---|
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clonal Evolution; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Female; GTP Phosphohydrolases; Humans; Leukemia, Myelomonocytic, Chronic; Membrane Proteins; Mice; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Receptor, Notch1; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2020 |
Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma.
Topics: Azacitidine; Child, Preschool; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Meningeal Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Nevus, Pigmented; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms | 2022 |